/SLGL
SLGL Stock - Sol-Gel Technologies Ltd.
Healthcare|BiotechnologyNASDAQ
$62.94-0.08%
$0.05 (-0.08%) • Jan 13
51
GoAI Score
GoAI Score
Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.HOLD
Medium Confidence
Momentum
Momentum Score
Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.100
Sentiment
Sentiment Score
Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).9
Risk Score
Risk Score
Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.66
Price Target
Price Target
Average analyst price target from the last quarter. Shows expected upside/downside from current price.+-20.6%upside
Target: $49.97
AI Analysis PreviewPremium
Real-time AI-powered market analysis
Precise entry/exit price targets
Risk assessment & position sizing
Unlock GoAI Insights for SLGL
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Buy/Sell Signals
94% win rate on Alpha signals
Deep Analysis
Institutional-grade thesis
Real-Time Alerts
SMS & push notifications
Risk Scoring
Multi-factor analysis
Free 14-day trial • No credit card required
Active Trade Setup
ENTRY ZONE$62.31 – $63.57
TARGET (TP)$50.00
STOP LOSS$57.90
RISK/REWARD1:-2.6
Premium members get real-time SMS alerts
Price Chart
Financial Statements
Revenue & Profitability Trend
← Swipe to see more →
Revenue
Net Income (Profit)
Net Loss
Key Metrics
Market CapN/A
P/E RatioN/A
Beta1.36
52W High$66.20
52W Low$4.02
Avg VolumeN/A
Income Statement (Fiscal Year)
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | $11.54M | $1.55M | $3.88M | $31.27M | $8.77M |
| Gross Profit | $11.30M | $-21,987,000 | $-8,799,000 | $10.89M | $-19,142,000 |
| Gross Margin | 98.0% | -1414.9% | -226.6% | 34.8% | -218.2% |
| Operating Income | $-12,014,000 | $-29,305,000 | $-16,244,000 | $2.96M | $-30,233,000 |
| Net Income | $-10,580,000 | $-27,238,000 | $-14,923,000 | $3.22M | $-29,290,000 |
| Net Margin | -91.7% | -1752.8% | -384.3% | 10.3% | -333.9% |
| EPS | $-0.38 | $-1.01 | $-0.65 | $1.40 | $-1.30 |
Company Overview
Sol-Gel Technologies Ltd., a clinical stage specialty pharmaceutical company, focuses on developing and commercializing topical dermatological drug products based on its proprietary microencapsulation delivery system in Israel. The company's lead product candidates include Twyneo, a novel, once-daily, non-antibiotic topical cream which has completed Phase III clinical trials for the treatment of acne vulgaris; Epsolay, a once-daily topical cream that has completed Phase III clinical trials for the treatment of papulopustular rosacea; SGT-210, which is in Phase I clinical trial for the treatment of palmoplantar keratoderma; and Erlotinib, Tapinarof, and roflumilast to treat psoriasis and other medical conditions. It is also involved in the development of generic topical dermatological drug products. The company has collaboration with Perrigo. Sol-Gel Technologies Ltd. was incorporated in 1997 and is headquartered in Ness Ziona, Israel.
Visit WebsiteRating Distribution
Strong Buy
0%
Buy / Outperform
1
50%
Hold / Neutral
1
50%
Sell / Underperform
0%
Analyst Consensus🟡 Mixed
1 Bullish1 Neutral/Bearish
Price Targets
$5
Average Target
↓ 92.5% Downside
Now
$4
Low
$5
Average
$6
High
Based on 2 analysts
Recent Analyst Actions
| Date | Firm | Action | Rating | Price Target |
|---|---|---|---|---|
| August 19th 2024 | Raymond James | Downgrade | Outperform | $4← $6 |
| October 21st 2022 | Jefferies | Resumed | Hold | $5.5 |
Earnings History & Surprises
SLGLBeat Rate
53%
Last 19 quarters
Avg Surprise
+39.8%
EPS vs Estimate
Beats / Misses
10/9
Last 12 quarters
Latest EPS
$-2.13
Q4 2025
EPS Surprise History
Q1 24
-6.3%
$-0.17vs$-0.16
Q2 24
-53.3%
$-0.23vs$-0.15
Q3 24
+135.0%
$0.07vs$-0.20
Q4 24
+92.3%
$-0.01vs$-0.13
Q1 25
-90.8%
$-0.21vs$-0.11
Q2 25
-90.9%
$-2.10vs$-1.10
Q3 25
+722.4%
$4.17vs$-0.67
Q4 25
-1.9%
$-2.13vs$-2.09
Beat Estimate
Missed Estimate
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q2 2026 | May 5, 2026 | $0.39 | — | — | — |
Q4 2025 | Nov 20, 2025 | $-2.09 | $-2.13 | -1.9% | ✗ MISS |
Q3 2025 | Aug 15, 2025 | $-0.67 | $4.17 | +722.4% | ✓ BEAT |
Q2 2025 | Apr 29, 2025 | $-1.10 | $-2.10 | -90.9% | ✗ MISS |
Q1 2025 | Mar 26, 2025 | $-0.11 | $-0.21 | -90.8% | ✗ MISS |
Q4 2024 | Nov 15, 2024 | $-0.13 | $-0.01 | +92.3% | ✓ BEAT |
Q3 2024 | Aug 16, 2024 | $-0.20 | $0.07 | +135.0% | ✓ BEAT |
Q2 2024 | May 20, 2024 | $-0.15 | $-0.23 | -53.3% | ✗ MISS |
Q1 2024 | Mar 13, 2024 | $-0.16 | $-0.17 | -6.3% | ✗ MISS |
Q4 2023 | Nov 9, 2023 | $-0.23 | $-0.21 | +8.7% | ✓ BEAT |
Q3 2023 | Aug 10, 2023 | $-0.26 | $-0.22 | +15.4% | ✓ BEAT |
Q2 2023 | May 12, 2023 | $-0.22 | $-0.41 | -86.4% | ✗ MISS |
Q1 2023 | Mar 10, 2023 | $-0.13 | $-0.25 | -92.3% | ✗ MISS |
Q4 2022 | Nov 10, 2022 | $-0.07 | $-0.15 | -114.3% | ✗ MISS |
Q3 2022 | Aug 4, 2022 | $-0.10 | $-0.01 | +90.0% | ✓ BEAT |
Q2 2022 | May 13, 2022 | $-0.30 | $-0.24 | +20.0% | ✓ BEAT |
Q1 2022 | Mar 30, 2022 | $0.41 | $0.61 | +48.8% | ✓ BEAT |
Q4 2021 | Nov 11, 2021 | $-0.07 | $0.05 | +171.4% | ✓ BEAT |
Q3 2021 | Aug 4, 2021 | $-0.20 | $-0.35 | -75.0% | ✗ MISS |
Q2 2021 | May 13, 2021 | $-0.49 | $-0.18 | +63.3% | ✓ BEAT |
Latest News
HC Wainwright & Co. Reiterates Buy on Sol-Gel Technologies, Maintains $50 Price Target
📈 PositiveBenzinga•Dec 22, 2025, 11:23 AM
Sol-Gel halts studies for rare disease therapy after trial setback
📉 NegativeSeeking Alpha•Dec 17, 2025, 01:25 PM
Sol-Gel Says Phase 1b Study Of Sgt-210 In Darier Disease Did Not Differentiate Versus Vehicle, Will Not Advance Program And Will Focus On Phase 3 Sgt-610 In Gorlin Syndrome
📉 NegativeBenzinga•Dec 17, 2025, 12:08 PM
Sol-Gel Technologies Q3 EPS $(2.13) Misses $(2.09) Estimate, Sales $400.000K Beat $300.000K Estimate
➖ NeutralBenzinga•Nov 20, 2025, 12:34 PM
HC Wainwright & Co. Maintains Buy on Sol-Gel Technologies, Raises Price Target to $50
📈 PositiveBenzinga•Oct 27, 2025, 11:04 AM
Sol-Gel Secures Health Canada Approval Of EPSOLAY For Treatment Of Inflammatory Lesions Of Rosacea In Adults, Partner Searchlight Pharma Preparing Canadian Launch
📈 PositiveBenzinga•Sep 4, 2025, 11:24 AM
Frequently Asked Questions about SLGL
What is SLGL's current stock price?
Sol-Gel Technologies Ltd. (SLGL) is currently trading at $62.94 per share. The stock has moved -0.08% today.
What is the analyst price target for SLGL?
The average analyst price target for SLGL is $50.00, based on 1 analyst.
What sector is Sol-Gel Technologies Ltd. in?
Sol-Gel Technologies Ltd. operates in the Healthcare sector, specifically within the Biotechnology industry. The company is traded on the NASDAQ exchange.
What is SLGL's market cap?
Sol-Gel Technologies Ltd. has a market capitalization of $0.18 billion, making it a small-cap company.
Does SLGL pay dividends?
No, Sol-Gel Technologies Ltd. does not currently pay a dividend to shareholders.
Similar Stocks
Healthcare SectorANEB
Anebulo Pharmaceuticals, Inc.
$1.11
Mkt Cap: $0.0B
CLNN
Clene Inc.
$5.10
Mkt Cap: $0.0B
COYA
Coya Therapeutics, Inc.
$4.62
Mkt Cap: $0.1B
MGNX
MacroGenics, Inc.
$1.75
Mkt Cap: $0.1B
OKYO
OKYO Pharma Limited
$3.11
Mkt Cap: $0.1B
ORMP
Oramed Pharmaceuticals Inc.
$3.39
Mkt Cap: $0.1B
OVID
Ovid Therapeutics Inc.
$1.65
Mkt Cap: $0.1B
PLRX
Pliant Therapeutics, Inc.
$1.29
Mkt Cap: $0.1B
TLSA
Tiziana Life Sciences Ltd
$1.35
Mkt Cap: $0.1B
ZNTL
Zentalis Pharmaceuticals, Inc.
$3.48
Mkt Cap: $0.3B
Explore stocks similar to SLGL for comparison